[Mechanism of the effect of LPSp on the production of anti-HBs in mice].
OBJECTIVE
To investigate the mechanism of the effect of avirulent Pantoea agglomerans lipopolysaccharide (LPSp) as the adjuvant of HBsAg on the production of anti-HBs in mice.


METHODS
The peritoneal macrophages of BALB/c mice were pulsed in vitro by HBsAg+LPSp, HBsAg, LPSp, and NS respectively. The levels of anti-HBs IgG in serum were determined by ELISA. The variation of phagocytosis of the macrophages was detected. The culture supernatants were harvested and assayed for TNF-alpha and NO. HBsAg-pulsed peritoneal macrophages in the presence or absence of LPSp were injected in the hind footpads of syngeneic mice. Lymph node cells were harvested and cultured by HBsAg. IL-4 and IFN-gamma in the supernatants were quantitated by ELISA.


RESULTS
The titer of anti-HBs IgG from the mice immunized with HBsAg-pulsed peritoneal macrophages treated with LPSp was higher than that of the mice immunized in the absence of LPSp. The phagocytosis rate of the LPSp-treated peritoneal macrophages was higher than that of the untreated macrophages. The level of TNF-alpha and NO of the LPSp-treated peritoneal macrophages was higher than that of the untreated macrophages. HBsAg-pulsed peritoneal cells in the presence of LPSp can induced higher production of IL-4 than those in the absence of LPSp.


CONCLUSIONS
LPSp can act as the adjuvant of HBsAg and effectively increase the anti-HBS in the mice immunized by HBsAg. LPSp can activate macrophages and stimulate HBsAg-pulsed macrophages to induce the production of IL-4 of lymph node cells.
Wang
Jian
J
Clinical Laboratory of the First Affiliated Hospital, Guangxi Medical University, Nanning 530021, China.
Leng
Jing
J
Wang
Qi-hui
QH
D000276:Adjuvants, Immunologic; D000818:Animals; D002478:Cells, Cultured; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006510:Hepatitis B Antibodies / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D009589:Nitrogen Oxides / Q000378:metabolism; D010587:Phagocytosis / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000276:Adjuvants, Immunologic; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D008070:Lipopolysaccharides; D009589:Nitrogen Oxides; D014409:Tumor Necrosis Factor-alpha; D015847:Interleukin-4; D007371:Interferon-gamma